{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:48:39Z","timestamp":1778280519368,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.vaccine.2017.01.066","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T03:45:42Z","timestamp":1486784742000},"page":"1530-1537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France"],"prefix":"10.1016","volume":"35","author":[{"given":"Muhamed-Kheir","family":"Taha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Cesar","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Liberator","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala-Eddine","family":"Deghmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomira","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.01.066_b0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/hv.22302","article-title":"The changing epidemiology of meningococcal disease in North America 1945\u20132010","volume":"9","author":"Baccarini","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.01.066_b0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2334-12-202","article-title":"Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010","volume":"12","author":"Dang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.066_b0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/INF.0000000000000282","article-title":"The clinical features and long-term sequelae of invasive meningococcal disease in children","volume":"33","author":"Stein-Zamir","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.01.066_b0020","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.066_b0025","unstructured":"Australian Government Department of Health. Meningococcal \u2013 Australian Meningococcal Surveillance Programme annual reports. <http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/cda-pubs-annlrpt-menganrep.htm> [accessed August 27, 2015]."},{"key":"10.1016\/j.vaccine.2017.01.066_b0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: Implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.066_b0035","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines \u2013 Advisory Committee on Immunization Practices (ACIP), 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.01.066_b0040","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.066_b0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.01.066_b0050","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.066_b0055","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u2a7e10 years at increased risk for serogroup B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.01.066_b0060","unstructured":"PubMLST. Neisseria sequence typing home page. University of Oxford. <http:\/\/pubmlst.org\/neisseria\/> [accessed January 6, 2016]."},{"key":"10.1016\/j.vaccine.2017.01.066_b0065","unstructured":"Bexsero\u00ae (meningococcal group B vaccine). Full Prescribing Information. Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA; 2015."},{"key":"10.1016\/j.vaccine.2017.01.066_b0070","unstructured":"Trumenba\u00ae (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc., Philadelphia, PA; 2014."},{"key":"10.1016\/j.vaccine.2017.01.066_b0075","unstructured":"European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe; 2012. <http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/Surveillance%20of%20IBD%20in%20Europe%202012.pdf> [accessed July 13, 2016]."},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2017.01.066_b0080","first-page":"25","article-title":"Principales caracteristiques epidemiologiques","volume":"2014","author":"Barret","year":"2012","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.vaccine.2017.01.066_b0085","first-page":"475","volume":"45\u201346","author":"Parent du Chatelet","year":"2011","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.vaccine.2017.01.066_b0090","unstructured":"Centers for Disease Control and Prevention. Meningococcal outbreaks. <http:\/\/www.cdc.gov\/meningococcal\/outbreaks\/index.html> [accessed January 12, 2016]."},{"key":"10.1016\/j.vaccine.2017.01.066_b0095","unstructured":"Haut Conseil de la sant\u00e9 publique. Avis: relatif \u00e0 l\u2019utilisation du vaccin Bexsero. <http:\/\/www.hcsp.fr\/Explore.cgi\/Telecharger?NomFichier=hcspa20131025_vaccmeningocoqueBBexsero.pdf> [accessed November 3, 2016]."},{"key":"10.1016\/j.vaccine.2017.01.066_b0100","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.066_b0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/hv.7.0.14564","article-title":"Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease","volume":"7","author":"Harris","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.01.066_b0110","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18\u201336 months: A phase 1 randomized-controlled clinical trial","volume":"31","author":"Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.01.066_b0115","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.066_b0120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","article-title":"A randomized, controlled, phase 1\/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents","volume":"32","author":"Nissen","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.01.066_b0125","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.066_b0130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/INF.0000000000001399","article-title":"Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains","volume":"36","author":"Harris","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.01.066_b0135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jpids\/piv039","article-title":"Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2017.01.066_b0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.066_b0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/JCM.01447-15","article-title":"Comparison of phenotypic and genotypic approaches to capsule typing Neisseria meningitidis using invasive and carriage isolate collections","volume":"54","author":"Jones","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.01.066_b0150","unstructured":"PubMLST. Bacterial isolate genome sequence database (BIGSdb). University of Oxford. <http:\/\/pubmlst.org\/software\/database\/bigsdb\/> [accessed January 6, 2016]."},{"key":"10.1016\/j.vaccine.2017.01.066_b0155","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.01.066_b0160","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.066_b0165","unstructured":"World Health Organization. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A\/C vaccines. Geneva, 8\u20139 March 1999. <http:\/\/apps.who.int\/iris\/bitstream\/10665\/66298\/1\/WHO_V%26B_99.19.pdf> [accessed April 4, 2016]."},{"key":"10.1016\/j.vaccine.2017.01.066_b0170","first-page":"289","article-title":"Serogroup B and C serum bactericidal assays","volume":"66","author":"Borrow","year":"2001","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.vaccine.2017.01.066_b0175","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: Longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2017.01.066_b0180","first-page":"178","article-title":"Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005","volume":"2006","author":"Rouaud","year":"2003","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.01.066_b0185","first-page":"15","article-title":"Community outbreak of group B meningococcal disease in southwest France--December 2008 to September 2009","volume":"2010","author":"Delisle","year":"2008","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.01.066_b0190","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0b013e31829aa63b","article-title":"A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups","volume":"32","author":"Hoiseth","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.01.066_b0195","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/CMR.7.4.559","article-title":"Current status of meningococcal group B vaccine candidates: capsular or noncapsular?","volume":"7","author":"Diaz Romero","year":"1994","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.01.066_b0200","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.01.066_b0205","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.01.066_b0210","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.01.066_b0215","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.vaccine.2005.12.059","article-title":"Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks","volume":"25","author":"Taha","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.066_b0220","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.38.9.3323-3328.2000","article-title":"Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team","volume":"38","author":"Tondella","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.01.066_b0225","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.066_b0230","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.066_b0235","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.01.066_b0240","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.066_b0245","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.01.066_b0250","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.066_b0255","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.066_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Imunogenicity and tolerability of a mulicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.01.066_b0265","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1586\/14760584.2015.1071670","article-title":"Multivalent meningococcal serogroup B vaccines: Challenges in predicting protection and measuring effectiveness","volume":"14","author":"Poolman","year":"2015","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.01.066_b0270","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.34293","article-title":"The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease","volume":"11","author":"Zlotnick","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.01.066_b0275","unstructured":"MacNeil J. Considerations for use of serogroup B meningococcal (MenB) vaccines in adolescents. <http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2015-06\/mening-03-macneil.pdf> [accessed April 4, 2016]."},{"key":"10.1016\/j.vaccine.2017.01.066_b0280","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.44.20949","article-title":"Four-month outbreak of invasive meningococcal disease caused by a rare serogroup B strain, identified through the use of molecular PorA subtyping, England, 2013","volume":"19","author":"Chatt","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.01.066_b0285","article-title":"A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013","volume":"20","author":"O'Connor","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.01.066_b0290","first-page":"1","article-title":"A cluster of invasive meningococcal disease revealed by the characterization of a novel serogroup B meningococcal clone","author":"Valinsky","year":"2015","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2017.01.066_b0295","unstructured":"Patel M. Use of serogroup B meningococcal vaccine during outbreaks on college campuses. <http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/min-archive\/min-2014-02.pdf> [accessed September 2, 2015]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17301469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17301469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:41:30Z","timestamp":1692682890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17301469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0264410X17301469"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}